What is ASCQR?

The Ambulatory Surgery Center Quality Reporting program is a complex program with multiple reporting requirements and deadlines. ASCQR is designed to promote higher quality, more efficient health care for Medicare beneficiaries through measurement. Under ASCQR, quality data reporting requirements for care rendered in an ASC setting were implemented starting with claims submitted for services beginning October 1, 2012.

ASCQR is required. Will you go it alone or get experienced help?

If you do not participate or fail to meet the ASCQR requirements, your center may see a 2% reduction to your CMS payment.

Helping ASCs with Quality Reporting

Miraca ASC Consulting Services help your center make sense of the requirements and deadlines throughout the year.

  • Our team of expert consultants work with you to ensure the ASC has an active Security Administrator for the QualityNet Secure Portal and is properly registered with the CDC to report ASC 8
  • We guide you through the registration process which can take up to 4 weeks to complete
  • Miraca’s staff consultants work with your billing team, security administrator and physicians to help you confirm that you’re meeting all program requirements
    • For your Billing Team
      We provide workflow support and guidance to your billing personnel to report ASC measures 1–5.
    • For your Security Administrator
      ASC 6, 7, 9, & 10 through Quality Net. ASC 8 must be reported through the CDC website. Miraca will also work with the Security Administrator to submit ASC-6 (Safe Surgery Checklist Use) and ASC-7 (ASC Facility Volume Data on Selected ASC Surgical Procedures).
    • For your Physicians
      ASC-9 (Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients), and ASC-10 (Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use).

ASCQR MEASURES

  • Measures 1–5 are claims-based—Miraca helps you ensure that G codes are included for revenue optimization
  • Measures 6, 7, 8 are web-based—we help you maximize your participation
  • Measures 9 and 10 are specific to pathology—we help you address workflow and pathology input

QUALITY MEASURES

GIQuIC is a GI-specific registry that captures the quality measures from the surgery center. It’s a qualified clinical data registry (QCDR) and is CMS-approved for reporting PQRS quality measures.

As a fee-based service, Miraca has enhanced interfaces with both ProVation MD and gMed to auto-populate the entry of pathology data in GIQuIC.

TECHNOLOGY OPTIMIZATION

  • Benefit from Miraca’s bi-directional ERW interfaces for submitting requisitions and receiving reports
  • Make the most of your technology through Miraca training on your interfaces and your practice workflow

HIPAA TRAINING

  • Get compliance training for your existing staff and new hires

SECURITY RISK ASSESSMENT

  • Understand where and how to improve your security
  • Stay compliant with security requirements

ACS/HOSPITAL COMPARE REVIEW

  • Understand the steps you can take to boost your CMS public ratings
  • See how the CMS website compares the ASCs in your market
  • Collect patient surveys—in 2018, at least 300 patient surgery surveys must be collected
    • Utilize our unique ERW interfaces to send procedure notes and images

ASCQR Web-Based Measures

Data collected January 1–December 31, 2015, should be submitted January 1–August 15, 2016, to determine the 2017 payment rate.

  • ASC-6: Safe Surgery Checklist Use
  • ASC-7: ASC Facility Volume Data on Selected ASC Surgical Procedures
  • ASC-8: Influenza Vaccination Coverage among Healthcare Personnel (data collection period: Oct. 1, 2015–March 31, 2016; submission period: Oct. 1, 2015–May 15, 2016)
  • ASC-9: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients
  • ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
  • ASC-11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NOTE: Data Submission Voluntary)

Collect data in January 1–December 31, 2016, to be submitted January 1–August 15, 2017, to determine the 2018 payment rate:

  • ASC-6: Safe Surgery Checklist Use
  • ASC-7: ASC Facility Volume Data on Selected ASC Surgical Procedures
  • ASC-8: Influenza Vaccination Coverage among Healthcare Personnel (data collection period: Oct. 1, 2015-March 31, 2016; submission period: Oct. 1, 2015-May 15, 2016)
  • ASC-9: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients
  • ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
  • ASC-11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NOTE: Data Submission Voluntary)

*National Healthcare Safety Network

Contact Miraca to learn how we can assist your practice.
Email HealthITConsulting@MiracaLS.com or call 866.588.3280.

Like many offices, Meaningful Use has been a challenge, but Miraca has been there to answer all our questions, walk us through changes, and most importantly keep us compliant.
— Susan Seidel, RN,
Office Manager, Stone Oak Dermatology, San Antonio, Texas


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading


October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading


October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading


September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading